Pfizer Long-Term Investments 2010-2024 | PFE
Pfizer long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- Pfizer long-term investments for the quarter ending September 30, 2024 were $10.762B, a 24.42% decline year-over-year.
- Pfizer long-term investments for 2023 were $15.368B, a 1.98% increase from 2022.
- Pfizer long-term investments for 2022 were $15.069B, a 30% decline from 2021.
- Pfizer long-term investments for 2021 were $21.526B, a 6.24% increase from 2020.
Pfizer Annual Long-Term Investments
(Millions of US $) |
| 2023 |
$15,368 |
| 2022 |
$15,069 |
| 2021 |
$21,526 |
| 2020 |
$20,262 |
| 2019 |
$20,147 |
| 2018 |
$2,767 |
| 2017 |
$7,015 |
| 2016 |
$7,116 |
| 2015 |
$15,999 |
| 2014 |
$17,518 |
| 2013 |
$16,406 |
| 2012 |
$14,149 |
| 2011 |
$9,814 |
| 2010 |
$9,747 |
| 2009 |
$13,122 |
Pfizer Quarterly Long-Term Investments
(Millions of US $) |
| 2024-09-30 |
$10,762 |
| 2024-06-30 |
$11,148 |
| 2024-03-31 |
$11,613 |
| 2023-12-31 |
$15,368 |
| 2023-09-30 |
$14,239 |
| 2023-06-30 |
$15,066 |
| 2023-03-31 |
$14,743 |
| 2022-12-31 |
$15,069 |
| 2022-09-30 |
$13,888 |
| 2022-06-30 |
$18,962 |
| 2022-03-31 |
$20,737 |
| 2021-12-31 |
$21,526 |
| 2021-09-30 |
$21,597 |
| 2021-06-30 |
$20,942 |
| 2021-03-31 |
$20,228 |
| 2020-12-31 |
$20,262 |
| 2020-09-30 |
$19,008 |
| 2020-06-30 |
$18,720 |
| 2020-03-31 |
$18,220 |
| 2019-12-31 |
$20,147 |
| 2019-09-30 |
$18,722 |
| 2019-06-30 |
$2,905 |
| 2019-03-31 |
$2,859 |
| 2018-12-31 |
$2,767 |
| 2018-09-30 |
$6,444 |
| 2018-06-30 |
$6,595 |
| 2018-03-31 |
$6,945 |
| 2017-12-31 |
$7,015 |
| 2017-09-30 |
$7,311 |
| 2017-06-30 |
$7,008 |
| 2017-03-31 |
$7,346 |
| 2016-12-31 |
$7,116 |
| 2016-09-30 |
$9,507 |
| 2016-06-30 |
$13,124 |
| 2016-03-31 |
$14,146 |
| 2015-12-31 |
$15,999 |
| 2015-09-30 |
$16,233 |
| 2015-06-30 |
$17,650 |
| 2015-03-31 |
$18,289 |
| 2014-12-31 |
$17,518 |
| 2014-09-30 |
$18,451 |
| 2014-06-30 |
$17,168 |
| 2014-03-31 |
$15,822 |
| 2013-12-31 |
$16,406 |
| 2013-09-30 |
$15,731 |
| 2013-06-30 |
$16,107 |
| 2013-03-31 |
$15,392 |
| 2012-12-31 |
$14,149 |
| 2012-09-30 |
$13,429 |
| 2012-06-30 |
$10,548 |
| 2012-03-31 |
$10,632 |
| 2011-12-31 |
$9,814 |
| 2011-09-30 |
$9,468 |
| 2011-06-30 |
$10,207 |
| 2011-03-31 |
$9,811 |
| 2010-12-31 |
$9,747 |
| 2010-09-30 |
$10,344 |
| 2010-06-30 |
$10,524 |
| 2010-03-31 |
$12,081 |
| 2009-12-31 |
$13,122 |
| 2009-09-30 |
$12,166 |
| 2009-06-30 |
$12,576 |
| 2009-03-31 |
$13,536 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
